Dr. Reddy’s Gains on EU Biosimilar Approval but Loses Momentum

As on 25 Nov 2025,

opened strong, gaining nearly 2% intraday after receiving European Commission approval for AVT03 (denosumab), a proposed biosimilar of Prolia and Xgeva used in treating osteoporosis. The development boosted sentiment early on, but after 12:15 PM, the stock began shedding its initial strength as profit-booking emerged. By the close, Dr. Reddy’s managed to hold a 0.8% gain, reflecting moderated buying interest despite a key regulatory milestone. 📌 Disclaimer: This content is for information only and not investment advice. Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered advisor before making any investment decisions.